ArticleJournal of multivariate analysis2025
A non-parametric U-statistic testing approach for multi-arm clinical trials with multivariate longitudinal data.
Article in Journal of multivariate analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Power and Sample Size Calculation for Multivariate Longitudinal Trials Using the Longitudinal Rank Sum Test.Statistics in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Randomized clinical trials (RCTs) often involve multiple longitudinal primary outcomes to comprehensively assess treatment efficacy. The Longitudinal Rank-Sum Test (LRST) [17], a robust U-statistics-based, non-parametric, rank-based method, effectively controls Type I error and enhances statistical power by leveraging the temporal structure of the data without relying on distributional assumptions. However, the LRST is limited to two-arm comparisons. To address the need for comparing multiple doses against a control group in many RCTs, we extend the LRST to a multi-arm setting. This novel multi-arm LRST provides a flexible and powerful approach for evaluating treatment efficacy across multiple arms and outcomes, with a strong capability for detecting the most effective dose in multi-arm trials. Extensive simulations demonstrate that this method maintains excellent Type I error control while providing greater power compared to the two-arm LRST with multiplicity adjustments. Application to the Bapineuzumab (Bapi) 301 trial further validates the multi-arm LRST's practical utility and robustness, confirming its efficacy in complex clinical trial analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.